TYPE 2 INFLAMMATION IS THE
UNDERLYING CAUSE OF CRSwNP
IN ~80% OF PATIENTS1,2,a

CRSwNP is a clinical syndrome characterized by inflammation of the nose and paranasal sinuses1

Coexisting Type 2 diseases are common, and often exacerbated, in
patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)1,3,4

Click on the airways to reveal more coexisting Type 2 inflammatory diseases

Coexisting Type 2 diseases
associated with CRSwNP2,4-6

Patients with severe asthma and CRSwNP have higher asthma symptom
scores, elevated exacerbation rates, and increased loss of smell
compared with asthma patients who have CRS without nasal polyposis4

Without treatment, CRSwNP can lead to7-9:

  • Loss of smell
  • Nasal obstruction/congestion that may cause difficulty with nasal breathing
  • Anterior/posterior rhinorrhea
  • Pain/pressure
  • Sleep disturbance
  • Chronic fatigue
  • Work absenteeism and reduced productivity

a In Western countries.

CRS, chronic rhinosinusitis; NSAID, nonsteroidal anti-inflammatory drug; QoL, quality of life.


References: 1. Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473-478. 2. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50 3. Bachert C, Gevaert E. Advances in rhinitis and rhinosinusitis in 2015. J Allergy Clin Immunol. 2016;138(5):1277-1283. 4. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53. 5. Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42. 6. Benjamin MR, Stevens WW, Li N, et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7(3):1010-1016. 7. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):25. doi:10.1186/1939-4551-7-25 8. Palmer J, Messina J, Biletch R, Grosel K, Mahmoud R. Health care for chronic rhinosinusitis (CRS) symptoms—a cross-sectional, population-based survey of US adults meeting symptom criteria for CRS. Poster presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; March 3-6, 2017; Atlanta, GA. 9. Liu T, Cooper T, Earnshaw J, Cervin A. Disease burden and productivity cost of chronic rhinosinusitis patients referred to a tertiary centre in Australia. Aust J Otolaryngol. 2018;1:5. doi:10.21037/ajo.2018.01.03